Sarepta Therapeutics (SRPT) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Sarepta Therapeutics’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Sarepta Therapeutics (SRPT) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Sarepta Therapeutics (SRPT) lobbying for?

The lobbying data shows that Sarepta Therapeutics hired multiple lobbying firms and lobbied on various general and specific issues related to taxation, budget/appropriations, Medicare/Medicaid, health issues, rare diseases, patient access treatments, prescription drug user fee program reauthorization, value-based contracting, transparency, waivers, and gene therapy. They also lobbied government agencies such as the House of Representatives, FDA, HHS, Senate, and CMS.

One could infer that Sarepta Therapeutics is lobbying on these issues to influence healthcare policies and regulations that may affect their business operations, such as gaining approval for their gene therapy products or obtaining funding for their rare disease treatments. Additionally, they may be lobbying for tax incentives and budget allocations that benefit their research and development efforts. Overall, their lobbying efforts aim to support their mission of developing innovative and effective treatments for patients with rare diseases.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore